Xeris Pharmaceuticals announces Gvoke HypoPen for severe hypoglycemia
Gvoke HypoPen is the first ready-to-use glucagon in a premixed autoinjector, with no visible needle
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
02 Jul 20
Gvoke HypoPen is the first ready-to-use glucagon in a premixed autoinjector, with no visible needle
01 Jul 20
The leader in self-monitoring of blood glucose in France will distribute Mallya connected device to pharmacists and will…
30 Jun 20
Abbott's continuous glucose monitoring will be combined with Tandem's insulin delivery systems for the development of new integrated…
25 Jun 20
ALRT partners with Bionime to Offer comprehensive diabetes solution at lower cvost than test supplies alone vailable in…
23 Jun 20
The Sugarmate app is designed to help people with diabetes visualize diabetes therapy data in innovative ways
18 Jun 20
Tandem Diabetes Care, a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance
15 Jun 20
The funds will be utilised in advancing new products designed specifically to reduce the burden of diabetes management
15 Jun 20
Tandem Diabetes Care, a leading insulin delivery and diabetes technology company, today presented positive real-world data from early use of
12 Jun 20
The MiniMed 780G hybrid closed-loop insulin pump system has been designed to better stabilise blood sugar levels and…
04 Jun 20
The study will evaluate Revita DMR, the first non-drug, non-surgical, disease-modifying therapy, to avoid need for insulin injections…